Sign up

Orbimed Advisors LLC

$5.3B assets · 121 holdings · Q2 2026 · Filed 14 AUG 2026

About Orbimed Advisors LLC’s 13F portfolio

Orbimed Advisors LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Orbimed Advisors LLC reported $5.3B across 121 US-listed positions (). Its largest position is EDGEWISE THERAPEUTICS INC (EWTX) at 12% of the reported book, and its ten biggest holdings make up 43% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$5.3B
Assets (13F)
#788
of 8,839 by size
121
Holdings
43%
Top-10 weight
67
Buys
47
Sells
Top holdings · Q2 2026
121 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: EWTX
EDGEWISE THERAPEUTICS INC
$41.37
−1.59%
12%
15.5M$630.5M
2
NASDAQ: ELVN
ENLIVEN THERAPEUTICS INC
$44.89
−4.18%
6.5%
6.8M$343.9M
3
NYSE: LLY
ELI LILLY & CO
$1,382.75
−2.32%
5.9%
258K$309.3M
4
NASDAQ: MBX
MBX BIOSCIENCES INC
$53.42
+0.60%
3.6%
3.4M$189.3M
5
NASDAQ: SVA
SINOVAC BIOTECH LTD
$6.47
0.00%
3.5%
2.7M$184.5M
6
NASDAQ: AZN
ASTRAZENECA PLC
$178.76
−1.93%
3.2%
916K$171.1M
7
NASDAQ: GPCR
STRUCTURE THERAPEUTICS INC
$17.36
−4.46%
2.2%
2.2M$118.6M
8
NASDAQ: SION
SIONNA THERAPEUTICS INC
$2.97
−3.26%
2.1%
2.6M$112.4M
9
NASDAQ: CRVS
CORVUS PHARMACEUTICALS INC
$10.19
+0.20%
2.0%
7.2M$107.0M
10
NASDAQ: AVBP
ARRIVENT BIOPHARMA INC
$10.90
+1.96%
2.0%
3.0M$105.2M
11
NASDAQ: GH
GUARDANT HEALTH INC
$145.14
+1.30%
1.7%
584K$87.6M
12
NASDAQ: ARGX
ARGENX SE
$941.25
−0.66%
1.6%
93K$86.2M
13
NYSE: MRK
MERCK & CO INC
$137.78
−3.90%
1.6%
663K$85.2M
14
NASDAQ: QURE
UNIQURE NV
$20.30
−2.31%
1.6%
1.8M$83.3M
15
NASDAQ: PRAX
PRAXIS PRECISION MEDICINES I
$305.19
+0.04%
1.5%
230K$77.0M
16
NYSE: EW
EDWARDS LIFESCIENCES CORP
$105.23
−0.19%
1.4%
835K$75.5M
17
NASDAQ: PRLD
PRELUDE THERAPEUTICS INC
$3.30
−0.60%
1.4%
13.7M$73.2M
18
NASDAQ: ABVX
ABIVAX SA
$83.83
+2.11%
1.4%
547K$72.8M
19
NASDAQ: DYN
DYNE THERAPEUTICS INC
$15.87
−0.94%
1.4%
3.2M$71.9M
20
NASDAQ: NTRA
NATERA INC
$289.50
+0.71%
1.3%
262K$71.1M
21
NASDAQ: CGON
CG ONCOLOGY INC
$80.00
+1.34%
1.3%
973K$69.1M
22
NYSE: UNH
UNITEDHEALTH GROUP INC
$349.91
−10.21%
1.3%
161K$67.0M
23
NASDAQ: SPRY
ARS PHARMACEUTICALS INC
$3.69
+1.10%
1.3%
8.3M$66.4M
24
NASDAQ: ASND
ASCENDIS PHARMA A/S
$270.33
−0.32%
1.2%
244K$65.2M
25
NYSE: HUM
HUMANA INC
$385.78
−12.98%
1.2%
164K$65.2M

Showing 1–25 of 121 positions on this page reported in this 13F.

Sector allocation
  • Healthcare97%
  • Industrials0.6%
Recent activity · vs 2026-03-31
Bought67
  • AddedLLYELI LILLY & CO+8.9%$309.3M
  • AddedAZNASTRAZENECA PLC+36.6%$171.1M
  • AddedGPCRSTRUCTURE THERAPEUTICS INC+49.7%$118.6M
  • AddedGHGUARDANT HEALTH INC+34.1%$87.6M
  • AddedPRAXPRAXIS PRECISION MEDICINES I+33.4%$77.0M
  • AddedPRLDPRELUDE THERAPEUTICS INC+25.8%$73.2M
  • AddedABVXABIVAX SA+17.4%$72.8M
  • AddedDYNDYNE THERAPEUTICS INC+10.9%$71.9M
  • AddedCGONCG ONCOLOGY INC+2.6%$69.1M
  • NewUNHUNITEDHEALTH GROUP INC—$67.0M
Sold47
  • ReducedELVNENLIVEN THERAPEUTICS INC−14.9%$343.9M
  • ReducedMBXMBX BIOSCIENCES INC−5.7%$189.3M
  • ReducedSIONSIONNA THERAPEUTICS INC−27.6%$112.4M
  • ReducedARGXARGENX SE−32.2%$86.2M
  • ReducedQUREUNIQURE NV−15.4%$83.3M
  • ReducedEWEDWARDS LIFESCIENCES CORP−32.2%$75.5M
  • ReducedBSXBOSTON SCIENTIFIC CORP−37.7%$63.3M
  • ReducedISRGINTUITIVE SURGICAL INC−24.3%$62.8M
  • ReducedXENEXENON PHARMACEUTICALS INC−15.8%$53.9M
  • ReducedSYKSTRYKER CORPORATION−12.8%$50.1M
5%+ Beneficial Ownership Stakes · 20 activist (13D) · 9 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
PRLD
Prelude Therapeutics Inc
13D16.0%12.9MFiled 23 APR 2026
2
QTTB
Q32 Bio Inc.
13D15.4% · 2 classes2.3MFiled 12 MAR 2026
3
EWTX
Edgewise Therapeutics, Inc.
13D14.5%15.3MFiled 12 MAY 2025
4
ADRX
ADARx Pharmaceuticals, Inc.
13D14.0%14.9MFiled 02 OCT 2026
5
BRVE
Braveheart Bio, Inc.
13D13.5%12.2MFiled 10 SEP 2026
6
ASPE
Aspen Neuroscience, Inc.
13D12.3%3.6MFiled 06 NOV 2026
7
TRAW
Traws Pharma, Inc.
13D11.9%1.9MFiled 05 MAY 2026
8
ETRA
Electra Therapeutics, Inc.
13D11.0%6.9MFiled 25 SEP 2026
9
CRVS
CORVUS PHARMACEUTICALS, INC.
13D10.3%8.6MFiled 27 JAN 2026
10
STTK
Shattuck Labs, Inc.
13D10.0% · 2 classes9.0MFiled 15 JUN 2026
11
XLO
Xilio Therapeutics, Inc.
13G10.0%642KFiled 15 MAY 2026
12
VYNE
Yarrow Bioscience, Inc.
13D10.0%266KFiled 05 AUG 2026
13
ACET
Adicet Bio, Inc.
13D9.6% · 2 classes14.8MFiled 10 OCT 2025
14
ELVN
Enliven Therapeutics, Inc.
13D9.5% · 2 classes6.8MFiled 24 JUN 2026
15
CMPX
Compass Therapeutics, Inc.
13D8.9%15.2MFiled 15 AUG 2025
16
WHWK
Whitehawk Therapeutics, Inc.
13G8.9% · 2 classes4.2MFiled 15 MAY 2025
17
BLSM
BlossomHill Therapeutics, Inc.
13D8.9%2.7MFiled 18 AUG 2026
18
SION
Sionna Therapeutics, Inc.
13D8.4% · 2 classes3.7MFiled 13 FEB 2025
19
NPCE
NeuroPace Inc
13G8.0%2.6MFiled 14 AUG 2025
20
FBRX
Forte Biosciences, Inc.
13G8.0%510KFiled 14 FEB 2025
21
MBX
MBX Biosciences, Inc.
13D7.7% · 2 classes3.6MFiled 11 FEB 2026
22
AVBP
ArriVent BioPharma, Inc.
13D7.5% · 2 classes3.0MFiled 13 AUG 2025
23
NSPR
InspireMD, Inc.
13G7.4%3.1MFiled 17 FEB 2026
24
SCTX
Scribe Therapeutics, Inc.
13D7.2%1.3MFiled 29 JUL 2026
25
IMA
ImageneBio, Inc.
13D6.9% · 2 classes774KFiled 30 JUL 2025

Showing 1–25 of 29 disclosed stakes. 10 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading Orbimed Advisors LLC’s 13F portfolio

Orbimed Advisors LLC’s $5.3B 13F book is spread across 121 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 43%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are EWTX, ELVN, LLY, MBX and SVA, led by EDGEWISE THERAPEUTICS INC (EWTX) at 12% of the portfolio. The heaviest sector exposure is Healthcare (97%), then Industrials (1%).

What Orbimed Advisors LLC changed last quarter

Between 2026-03-31 and Q2 2026, Orbimed Advisors LLC was a net buyer: it opened 35 new positions and added to 32 more, while trimming 26 and closing 21 outright. Against a 121-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ELI LILLY & CO (LLY), and its biggest reduction was ENLIVEN THERAPEUTICS INC (ELVN).

What a 13F does and doesn’t reveal

A 13F captures only Orbimed Advisors LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Orbimed Advisors LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Orbimed Advisors LLC's profile on this page is built directly from those filings.

How current is the 13F data on Orbimed Advisors LLC's page?

It reflects Orbimed Advisors LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Orbimed Advisors LLC files its next quarterly report, this page refreshes automatically.

Can I see Orbimed Advisors LLC's complete list of holdings?

This page highlights Orbimed Advisors LLC's largest positions rather than all 121 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Orbimed Advisors LLC's filings.

Does a 13F show everything Orbimed Advisors LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Orbimed Advisors LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Orbimed Advisors LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.